3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
3
Thoracic
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Breast
1
Conditions
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Ovarian Neoplasms
1
Neoplasms, Squamous Cell
1
Melanoma
1
Esophageal Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma, Hepatocellular
1
Breast Neoplasms
1
Interventions
Paclitaxel
100
Trastuzumab
81
pembrolizumab
78
Fulvestrant
68
Cyclophosphamide
66
Carboplatin
49
Capecitabine
47
Docetaxel
45
palbociclib
41
Lapatinib
40
Letrozole
37
Doxorubicin
29
olaparib
28
Taxes
28
Nivolumab
25
Magnetic Resonance Spectroscopy
25
Gemcitabine
25
130-nm albumin-bound paclitaxel
25
Everolimus
23
Biopsy
23
ribociclib
22
abemaciclib
21
Specimen Handling
21
Albumin-Bound Paclitaxel
21
Cisplatin
20
Radiotherapy
19
Bevacizumab
19
Ado-Trastuzumab Emtansine
19
pertuzumab
17
Alpelisib
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
High-Intensity Focused Ultrasound Ablation
×
Breast
×
Clear all
NCT04116320
2025-07-14
AM-003
University of Virginia
Phase 1
Terminated
5 enrolled